ABSTRACT
Coinfection with Mycobacterium tuberculosis [tuberculosis (TB)] and with hepatitis B and C viruses presents unique challenges in the management of the HIV-infected individuals. Globally, TB accounts for approximately 13% of deaths of individuals with AIDS (1), and interactions between rifamycins used to treat TB and some antiretroviral agents may add complexity to the treatment of both the infections. The increasing prevalence of strains resistant to conventional therapy is particularly alarming and poses great challenges, particularly in resource-limited settings where access to resistance testing is often nonexistent.
